Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 6
2005 5
2006 8
2007 5
2008 6
2009 4
2010 7
2011 6
2012 7
2013 10
2014 8
2015 11
2016 7
2017 6
2018 2
2019 1
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Available evidence on HIFU for focal treatment of prostate cancer: a systematic review.
Bakavicius A, Marra G, Macek P, Robertson C, Abreu AL, George AK, Malavaud B, Coloby P, Rischmann P, Moschini M, Rastinehad AR, Sidana A, Stabile A, Tourinho-Barbosa R, de la Rosette J, Ahmed H, Polascik T, Cathelineau X, Sanchez-Salas R. Bakavicius A, et al. Among authors: rischmann p. Int Braz J Urol. 2022 Mar-Apr;48(2):263-274. doi: 10.1590/S1677-5538.IBJU.2021.0091. Int Braz J Urol. 2022. PMID: 34003610 Free PMC article. Review.
Cellular Senescence in Renal and Urinary Tract Disorders.
Santin Y, Lluel P, Rischmann P, Gamé X, Mialet-Perez J, Parini A. Santin Y, et al. Among authors: rischmann p. Cells. 2020 Nov 5;9(11):2420. doi: 10.3390/cells9112420. Cells. 2020. PMID: 33167349 Free PMC article. Review.
Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement.
Ganzer R, Arthanareeswaran VKA, Ahmed HU, Cestari A, Rischmann P, Salomon G, Teber D, Liatsikos E, Stolzenburg JU, Barret E. Ganzer R, et al. Among authors: rischmann p. Prostate Cancer Prostatic Dis. 2018 Jun;21(2):175-186. doi: 10.1038/s41391-018-0042-0. Epub 2018 May 9. Prostate Cancer Prostatic Dis. 2018. PMID: 29743538 Free article. Review.
[ BCG-immunotherapy and bladder cancer].
Rischmann P. Rischmann P. Prog Urol. 2008 May;18 Suppl 5:S93. doi: 10.1016/S1166-7087(08)72483-7. Prog Urol. 2008. PMID: 18585633 French. No abstract available.
Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives.
Bach T, Muschter R, Herrmann TR, Knoll T, Scoffone CM, Laguna MP, Skolarikos A, Rischmann P, Janetschek G, De la Rosette JJ, Nagele U, Malavaud B, Breda A, Palou J, Bachmann A, Frede T, Geavlete P, Liatsikos E, Jichlinski P, Schwaibold HE, Chlosta P, Martov AG, Lapini A, Schmidbauer J, Djavan B, Stenzl A, Brausi M, Rassweiler JJ. Bach T, et al. Among authors: rischmann p. BJU Int. 2015 Jan;115(1):14-23. doi: 10.1111/bju.12664. Epub 2014 Jul 14. BJU Int. 2015. PMID: 25646531 Review.
[The level of evidence for the use of biomarkers in the early detection of prostate cancer].
Lamy PJ, Gauchez AS, Salomon L, Haugh M, Ceraline J, Fulla Y, Georges A, Larré S, Loric S, Luporsi E, Martin PM, Mazerolles C, Molinié V, Mongiat-Artus P, Piffret J, Thuillier F, Perrin P, Rebillard X; Groupe de biologie de la prostate. Lamy PJ, et al. Ann Biol Clin (Paris). 2016 Mar-Apr;74(2):227-32. doi: 10.1684/abc.2016.1128. Ann Biol Clin (Paris). 2016. PMID: 27029727 Free article. Review. French.
86 results